Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration‐resistant prostate cancer treated with abiraterone or enzalutamide
Abstract
Abiraterone acetate and enzalutamide are two common therapies for metastatic castration‐resistant prostate cancer (mCRPC) that have shown improved overall survival (OS). The drugs have different mechanisms of action with limited comparative trials to evaluate treatment in patients with comorbidities such as obesity and diabetes. This is important since abiraterone requires the co‐administration of prednisone. We assessed the relationship between body mass index (BMI), hemoglobin A1c (HbA1c), treatment, and survival in mCRPC.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 01, 2023
- Source ID
- 10.1002/pros.24644
Entities
People
- Forest Riekhof
- Martin W Schoen
- Nina Cheranda
- Srinivas Govindan
- Suhong Luo
Organizations
- Prostate Cancer Foundation
- Saint Louis University
- United States Department of Defense
- Washington University in St. Louis